Half-Life

Half-Life refers to the time required for the concentration of a drug or biologic in the body to decrease by 50%, representing a key pharmacokinetic parameter influencing dosing frequency, exposure profiles, and therapeutic consistency. Half-life depends on absorption, distribution, metabolism, and elimination processes, varying widely across small molecules and biologics. For therapeutic antibodies, half-life often extends for days to weeks due to FcRn-mediated recycling.

The pharmaceutical industry designs dosing regimens around half-life to balance efficacy, safety, and patient convenience. Long half-life therapies enable less frequent dosing, improving adherence, while short half-life drugs may offer flexibility for rapid titration or reduced long-term exposure risk. Drug developers employ half-life extension strategies such as pegylation, Fc fusion, albumin binding, or formulation-based sustained release systems to enhance clinical utility. Regulatory submissions include half-life data supporting dosing recommendations and labelling. As novel modalities emerge and personalised dosing becomes more common, half-life remains fundamental for optimising therapeutic exposure and ensuring predictable clinical performance.